A Study of CIN-107 in Adults With Primary Aldosteronism

Primary Aldosteronism Clinical Trial

Official title:

A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04605549
• Other study ID #: CIN-107-122
• Secondary ID: D6970C00001
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 8, 2021
• Est. completion date: October 10, 2024

Study information

• Verified date: May 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.

Description:

For patients in Part 1 only :

The treatment duration for patients who complete all 3 dose levels, and who opt not to continue in the extension part of the study, is 12 weeks. For patients who do not complete up-titration, the treatment duration will include at least 4 weeks of dosing with the final dose level. If down-titration of CIN-107 dose is determined at Visit 6 (Week 9), the total treatment duration may be extended to 13 weeks to allow sufficient time for CIN-107 treatment effect at the final dose to be assessed. If the final dose of CIN-107 is reached before week 8 (Visit 5) and no up-titration occurs at Visit 5, the patients will be encouraged to continue CIN-107 treatment till Visit 7 for a total of 12 weeks of treatment. The patients who opt not to continue to Part 2 will not receive any study drug and will return for their safety follow up visit (Visit 8) in 2 weeks.

For patients who opt to continue in the extension part (Part 2) of the study:

Patients will continue to receive their dose of baxdrostat and be instructed to measure BP at least once every week prior to dosing with CIN-107 in the morning, during the extension phase. Safety surveillance will be conducted if clinically indicated. Repeat and unscheduled testing for serum potassium may be measured at the investigator's clinical site or at local laboratory for a faster turn-around time to allow clinical assessment. These patients entering part 2 will skip Visit 8 and their next visit will be Visit 9.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: October 10, 2024
• Est. primary completion date: October 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

1. Have been diagnosed with PA.

2. Are taking mineralocorticoid receptor antagonist (MRA) to control BP; or are newly diagnosed with PA and have not started MRA treatment.

3. Are willing and able to cease dosing of MRA for up to 4 weeks in patients taking MRA.

4. Are willing to be compliant with the contraception and reproduction restrictions of the study.

5. Have increased SBP by = 20 mmHg or have SBP = 160 mmHg after dosing of MRA treatment is ceased for up to 4 weeks duration, or have SBP = 150 mmHg for patients who are newly diagnosed with PA and have not taken an MRA in the past 12 weeks.

Exclusion Criteria:

1. At Screening Visit, have a single occurrence of mean seated SBP > 180 mmHg or DBP > 110 mmHg if not taking an MRA; or have a mean seated SBP = 160 mmHg or DBP = 100 mmHg if currently taking an MRA.

2. Have a body mass index > 45 kg/m2.

3. Have had a previous surgical intervention for an adrenal adenoma or have a planned adrenal carcinoma, adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study.

4. Have a documented estimated glomerular filtration rate < 45 mL/min/1.73 m2.

5. Have a planned dialysis, kidney transplantation or any major surgical procedure during the course of the study.

6. Have known documented New York Heart Association class III or IV chronic heart failure.

7. Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before the Screening Visit.

8. Have known current severe left ventricular outflow obstruction.

9. Have had major cardiac surgery within 6 months before the Screening Visit.

10. Have a history of, or currently experiencing, clinically significant arrhythmias.

11. Have had a prior solid organ transplant or cell transplant.

12. Are positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen.

13. Have typical consumption of > 14 alcoholic drinks weekly.

Related Conditions & MeSH terms

• Hyperaldosteronism
• Primary Aldosteronism

Intervention

Drug:
• CIN-107 2 mg dosing
One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
• CIN-107 4 mg dosing
Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
• CIN-107 8 mg dosing
Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.

Locations

Country	Name	City	State
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Baltimore	Maryland
United States	Research Site	Chicago	Illinois
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Columbus	Ohio
United States	Research Site	Dallas	Texas
United States	Research Site	Greenbrae	California
United States	Research Site	Rochester	Minnesota
United States	Research Site	San Francisco	California
United States	Research Site	West Hollywood	California

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability of CIN-107	Outcome measure is overall safety with is a composite of the following individual parameters (unit of measure in brackets): Adverse Events [number of events]; ECGs [PR interval (msec), RR interval (msec), or QTcF interval (msec); clinically significant ECG findings that are detected during the study will be reported as adverse events]; Clinical laboratory evaluations including standard safety chemistry panel, hematology, coagulation, and urinalysis [clinically significant abnormal laboratory findings that are detected during the study will be reported as adverse events]; Vital signs [pulse, temperature, heart rate and blood pressure] and physical examination data changes noted as clinically significant abnormalities that arise during the study will be recorded as adverse events	74 Weeks
Primary	Change in mean seated systolic blood pressure (SBP)	Effectiveness measured by change in mean seated SBP after 12 weeks of treatment in patients with PA	after 12 weeks of treatment
Secondary	Change in mean diastolic blood pressure (DBP)	Comparison of changes in mean SBP after 12 weeks of treatment in patients with PA.	after 12 weeks of treatment
Secondary	The percentage of patients achieving a seated blood pressure (BP) response <140/90 mmHg	The percent of patients who achieved a seated BP response <140/90 mmHg after CIN107 treatment will be evaluated at each dose level at Week 12.	at Week 12
Secondary	The percentage of patients achieving a seated BP response <130/80 mmHg	The percent of patients who achieved a seated BP response <130/80 mmHg after CIN107 treatment will be evaluated at each dose level at Week 12.	at Week 12
Secondary	The percentage of patients achieving either: - a plasma aldosterone concentration (PAC) < 15 ng/dL and a plasma renin activity (PRA) = 0.5 ng/mL/h; or - an ARR < 15; or - unsuppressed renin activity PRA = 1.0 ng/mL/h		after 12 weeks of treatment